In September 2023, early career hematologists from 16 countries involved in the clinical management of hemophilia gathered in Brussels, Belgium, to attend the two-day interactive educational MOVE Haemophilia 2023 meeting.

 

A faculty of internationally renowned experts in hemophilia care addressed a range of topics, including:

  • Factor replacement vs non-factor replacement therapy
  • Management of inhibitors
  • Surgery
  • Co-morbidities
  • Joint health
  • Optimising prophylaxis in children and adults
  • Effective communication for patients and families

 

The experts have developed two downloadable pdf slide sets to summarise the presentations. Find them under the Downloads tab.

 

Clinical Takeaways

  • Factor replacement therapy is a flexible and effective therapeutic option, both for prophylaxis and treatment of bleeds
  • Non-factor therapy is an effective treatment for severe hemophilia A and severe hemophilia B patients with inhibitors and can reduce the treatment burden compared to factor replacement therapy
  • The goal of hemophilia management should in the era of available non-factor therapies still be tolerance towards the deficient factor and ≥1 immune tolerance induction attempt should be considered in patients with persistent inhibitors.
  • Future clinical management should be individualised to minimise treatment burden, possibly by predictive tools.
  • Co-morbidities in people with hemophilia (PWH) are increasingly reported, predominantly in older PWH. Clinical practice guidance providing recommendations on antithrombotic therapy is available.
  • Physiotherapy remains crucial in PWH, both in those treated with evolving therapies and in those not receiving adequate treatment.
  • Laboratory testing of factor concentrates can vary between different methodologies. WFH recommends that laboratories use a FVIII/FIX assay that has been validated for use with the specific concentrates used for treatment.

Educational objectives

  • Be able to implement international guidelines for hemophilia in clinical practice, as relevant to the European and Middle Eastern region
  • Share and learn from best practices around the practicalities of hemophilia care
  • Be inspired to collaborate with MDT-members and patients to deliver shared care

Dr Ana Boban is Head of Haemophilia Centre at the University Hospital Centre Zagreb and Associate Professor of Internal Medicine at the School of Medicine of the University of Zagreb, Croatia. She has specialist degrees in Internal Medicine and Haematology. Dr Boban’s clinical work is in the field of benign haematology with the focus on bleeding disorders and thrombosis. Dr Boban is a member of national and international scientific and medical societies in the field of haemostasis and thrombosis and is currently serving as Executive Committee member of EAHAD. Dr Boban’s research interests include clinical haemophilia, carriers of haemophilia, von Willebrand disease, anticoagulant treatments and ITP.

Prof. Ana Boban has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, CSL Behring, Novo Nordisk, Octopharma, Pfizer, Roche, Sobi, Swixx Biopharma and Takeda. 

Christoph Königs has been based at the Paediatric Haemophilia Centre, University Hospital Frankfurt, Germany since 2002. He received his degree in science from Monash University, Melbourne, Australia in 1998 and his medical degree from Goethe University Frankfurt, Germany in 2002. For both his MD and PhD thesis, Christoph isolated ligands to clinically relevant structures of protein receptors and RNA. The main clinical and scientific interest of his research team is the understanding and modification of the immune response to coagulations factors. His main clinical focus is developing and improving therapies for children and adolescents with coagulation disorders with a focus on patient education and shared decision making. Christoph specialises in paediatrics and adolescent medicine and also in haemostasis. He is a member of several national and international scientific societies and committees. He co-chairs the Standing Committee Haemophilia of the Society for Thrombosis and Haemostasis (GTH), the National Registry on PUPs with Newly Diagnosed Haemophilias in Germany “GEPHARD” and the Scientific Advisory Council of PedNet. Christoph works closely with German patient organizations i.e. as a deputy chair of the medical advisory board.

Lund University and Skåne University Hospital in Malmö, Sweden. Jan Astermark is Professor in Clinical Coagulation Medicine at Lund University, Senior Consultant and Director of the Center for Thrombosis and Hemostasis in Malmö and Assistant Head of the Department of Translational Medicine in Malmö/Lund, Sweden. He is a specialist in haematology, coagulation disorders and internal medicine. He is a reviewer for haematology journals, and has published a number of original articles, review articles and book chapters in the field of haemophilia and coagulation disorders.

Prof. Jan Astermark has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, CSL Behring, Novo Nordisk, Octopharma, Roche, Sobi and Takeda/Shire. 

Programme summary
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Sobi.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HEMOSTASIS CONNECT

HEMOSTASIS CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Pfizer, Takeda, Viatris and Pentapharm.

Meet the experts

Other programmes of interest

Podcast
Hemostasis and bleeding disorders 
Thrombophilia: Clinical overview and impact on patients

Part 1 of a thrombophilia podcast series

Experts
Prof. Cedric Hermans, Prof. Sabine Eichinger
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2024

Educational programme supported by an Independent Medical Education grant from Pentapharm.
Podcast
Rare diseases Hemostasis and bleeding disorders 
Rare diseases: gene therapy and gene-modified cell therapies

Current role, potential and the example of hemophilia

Experts
Prof. Cedric Hermans, Prof. Miguel Escobar
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Dec 2023

Educational programme supported by an Independent Medical Education grant from American Society of Gene + Cell Therapy and Pfizer.
Podcast

Episode

4

of 4

episode
Hemostasis and bleeding disorders 
Perioperative thromboprophylaxis revisited

Minimising the risk of thrombosis in surgical patients

Experts
Prof. Dimitrios Tsakiris, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 19 MIN
  • calendar Nov 2023

Educational programme supported by an Independent Medical Education grant from Viatris.
Podcast

Episode

3

of 4

episode
Hemostasis and bleeding disorders 
VTE: What is the optimal duration of antithrombotic treatment?

Part 3 of a 4-part series on thrombosis

Experts
Prof. Dimitrios Tsakiris, Prof. Jerzy Windyga
Endorsed by
Fundacja Trombofilia i Zakrzepica
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Oct 2023

Educational programme supported by an Independent Medical Education grant from Viatris.
Podcast

Episode

2

of 4

episode
Hemostasis and bleeding disorders Oncology 
Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Sep 2023

Educational programme supported by an Independent Medical Education grant from Viatris.
Haemostasis expert panel Interactive e-learning
Hemostasis and bleeding disorders 
Normalising Haemostasis in Haemophilia: Panel Discussion and E-learning

Will the expert panellists change the way you think about managing haemophilia?

Experts
Prof. Pål Andrè Holme, Prof. Niamh O'Connell, Assoc. Prof. Jan Blatný
  • download Downloadable
    Resources
  • clock 45 MIN
  • calendar Sep 2023

Educational programme supported by an independent medical education grant from Sobi.